NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a prominent player in the ophthalmic disease management sector, has announced plans to offer an additional $50 million in senior unsecured notes, aimed at bolstering its growth initiatives. This issuance of 8.625% senior unsecured notes, set to mature in 2030, marks a strategic move for the company amid its expansion efforts.
Details of the Offering
The proposed offering will consist of $50 million in aggregate principal amount of Harrow's 2030 Notes. These notes will be guaranteed on a senior unsecured basis by both existing and future wholly-owned domestic subsidiaries of the company. The issuance is subject to market conditions and other criteria, highlighting the company's cautious yet ambitious approach to financing its growth. Learn more on Investopedia.
Harrow's management believes that tapping into the debt market at this juncture will provide the necessary capital to fund various corporate initiatives. The company aims to utilize the net proceeds from this offering for general corporate purposes, which may include accelerating growth through new product launches and supporting ongoing product development activities.
Strategic Growth Initiatives
The funds raised from this offering will also play a critical role in facilitating future strategic business development opportunities. Harrow has been actively exploring avenues to enhance its product portfolio and expand its market reach in North America. By securing additional capital through these notes, the company intends to position itself more favorably against competitors in the ophthalmic sector.
"This offering represents a significant step in our ongoing efforts to strengthen our balance sheet and invest in growth-oriented initiatives," said Harrow's management. The focus on new product development is particularly crucial as the company seeks to introduce innovative solutions to meet the evolving needs of ophthalmic care.
Market Conditions and Investor Interest
The offering comes at a time when investor interest in healthcare and specialized pharmaceuticals is on the rise. Harrow, with its established reputation in ophthalmic disease management, is well-positioned to attract investors looking for opportunities in this niche market. The 8.625% interest rate on the notes is competitive, reflecting the company's strong market standing and the perceived risk associated with the offering.
Potential investors will have access to a confidential offering memorandum that outlines the terms and conditions of the notes. This memorandum serves as a tool for eligible investors to assess the opportunity and make informed decisions regarding their participation in the offering. However, it is important to note that this announcement is not an offer to sell, nor a solicitation to buy any securities.
Looking Ahead
As Harrow moves forward with this offering, the company remains committed to its long-term vision of enhancing patient outcomes through innovative ophthalmic solutions. The additional capital is expected to provide a buffer for ongoing development projects and support the company's strategic objectives.
Harrow's leadership views this as a pivotal moment for the company, aligning its financial strategies with its overarching goal of sustainable growth. The management is optimistic about the future and is eager to implement the plans laid out with the proceeds from this offering.
In summary, Harrow's decision to expand its offering of senior unsecured notes underscores its commitment to growth and innovation within the ophthalmic disease management space. With the new capital, the company anticipates making significant strides in product development and market expansion, ultimately benefiting patients and investors alike.
Originally reported by Benzinga. View original.